However, the Lung-MAP SWOG S1400G trial (NCT02154490) found that talazoparib (Talzenna) had a lower ORR of 4% in patients with advanced refractory lung squamous cell carcinoma, specifically in tumors with BRCA1/2, ATM, ATR, and PALB2 mutations (Owonikoko et al., 2021). This evidence concerns the gene ATR and squamous cell lung carcinoma.